ArticleClinical transplantation2026
Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients.Clinical transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
aimsPost liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long-term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB-4) score and FibroScan.
methodsIn the Danish Comorbidity in Liver Transplant Recipients study (DACOLT) we included 105 LT recipients at Aarhus University Hospital. We reviewed patient records and collected plasma for measurements of sCD163 and FIB-4. Liver stiffness was assessed using FibroScan. Liver biopsies performed <6 months before or after inclusion (n = 33) were investigated by the Banff score and the METAVIR fibrosis score.
resultsThe majority (86%) had FibroScan with transient elastography <8 kPa. Plasma sCD163 correlated significantly with liver stiffness (ρ = 0.38, p < 0.001) and remained independently associated after multivariable adjustment (β = 0.14, p < 0.0002), corresponding to a 15.2% increase in liver stiffness per 1 mg/L increase in sCD163. In patients with liver biopsies, sCD163 levels were significantly higher in those with METAVIR stage F2-F4 compared to F0-F1 (5.04 vs. 2.35 mg/L, p = 0.018), and sCD163 correlated with histological fibrosis stage (ρ = 0.40, p = 0.029). At a cutoff of 3.86 mg/L, sCD163 identified METAVIR F2-4 fibrosis with 80% sensitivity and 85% specificity (AUC = 0.94).
conclusionsIn this cohort of LT recipients, sCD163 was associated with both liver stiffness and histological fibrosis. These findings support sCD163 as a promising noninvasive biomarker for detection and monitoring of liver fibrosis post-LT, warranting evaluation in larger, prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.